Viatris Inc

VTRSSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1792044

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$15.4B	$16.2B	$17.8B	$11.8B	$11.4B
Cost of Goods and Services Sold	$9.0B	$9.8B	$12.3B	$8.1B	$7.6B
Gross Profit	$6.4B	$6.5B	$5.6B	$3.8B	$3.9B
Research and Development Expense	—	—	—	—	$639.9M
Selling, General and Administrative Expense	$4.1B	$4.2B	$4.5B	$3.3B	$2.6B
Operating Expenses	$5.7B	$4.9B	$5.6B	$4.0B	$3.2B
Operating Income (Loss)	$766.2M	$1.6B	-$34.0M	-$210.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$41.5B	$47.7B	$50.0B	$54.8B	$61.6B
Assets, Current	$9.5B	$13.0B	$10.6B	$10.9B	$12.9B
Cash and Cash Equivalents, at Carrying Value	$991.9M	$1.3B	$701.2M	$844.4M	$475.6M
Accounts Receivable, after Allowance for Credit Loss, Current	$3.2B	$3.7B	$3.8B	$4.3B	$4.8B
Inventory, Net	$3.9B	$3.5B	$3.5B	$4.0B	$5.5B
Liabilities	$22.9B	$27.2B	$28.9B	$34.4B	$38.6B
Liabilities, Current	$5.8B	$7.8B	$6.7B	$9.9B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$2.9B	$3.0B	$3.0B	$1.2B	$1.8B
Net Cash Provided by (Used in) Investing Activities	-$864.5M	$1.5B	-$117.8M	-$301.1M	-$525.4M
Net Cash Provided by (Used in) Financing Activities	-$2.3B	-$3.9B	-$3.0B	-$605.7M	-$1.2B
Payments to Acquire Property, Plant, and Equipment	$377.0M	$406.0M	$457.2M	$243.0M	$213.2M
Payments for Repurchase of Common Stock	$250.0M	$0.00	$0.00	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)